Reply to “Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R-Related Leukoencephalopathy”

Philip W. Tipton; Daniel Kenney-Jung; Beth K. Rush; Erik H. Middlebrooks; David Nascene; Balvindar Singh; Shernan Holtan; Ernesto Ayala; Daniel F. Broderick; Troy Lund; Zbigniew K. Wszolek

doi:10.1002/mds.29018

Reply to “Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R-Related Leukoencephalopathy”

Philip W. Tipton, Daniel Kenney-Jung, Beth K. Rush, Erik H. Middlebrooks, David Nascene, Balvindar Singh, Shernan Holtan, Ernesto Ayala, Daniel F. Broderick, Troy Lund, Zbigniew K. Wszolek

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1109-1110
Number of pages	2
Journal	Movement Disorders
Volume	37
Issue number	5
DOIs	https://doi.org/10.1002/mds.29018
State	Published - May 2022

Keywords

CSF1R-related leukoencephalopathy
genetics; treatment
stem cell transplantation

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/mds.29018

Cite this

@article{bba984f377254c91b455a41e746995fb,

title = "Reply to “Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R-Related Leukoencephalopathy”",

keywords = "CSF1R-related leukoencephalopathy, genetics; treatment, stem cell transplantation",

author = "Tipton, {Philip W.} and Daniel Kenney-Jung and Rush, {Beth K.} and Middlebrooks, {Erik H.} and David Nascene and Balvindar Singh and Shernan Holtan and Ernesto Ayala and Broderick, {Daniel F.} and Troy Lund and Wszolek, {Zbigniew K.}",

note = "Funding Information: E.H.M. receives research support from Mayo Clinic Focused Team Research program; Mayo Clinic Research Accelerator for Clinicians Engaged in Research program; Boston Scientific Corp; Varian Medical Systems, Inc.; and the National Institutes of Health (R33‐CA240181). He is also consultant for Boston Scientific Corp. Funding Information: Z.K.W. is partially supported by the NIH/NIA and NIH/NINDS (1U19AG063911, FAIN: U19AG063911), Mayo Clinic Center for Regenerative Medicine, and Mayo Clinic in Florida Focused Research Team Program and the gifts from the Donald G. and Jodi P. Heeringa Family and the Haworth Family Professorship in Neurodegenerative Diseases fund, the Albertson Parkinson's Research Foundation, and Ann B. Smith Research Fund. He serves as Principal investigator or co‐principal investigator for Biohaven Pharmaceuticals, Inc. (BHV4157‐206 and BHV3241‐301); Neuraly, Inc. (NLY01‐PD‐1); and Vigil Neuroscience, Inc. (VGL101‐01.001 and VGL101‐01.002). He serves as co‐PI for the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience, Inc. Funding Information: D.K.‐J. is partially supported by grants from the Rare Disease Foundation and CFC International and is Co‐I on Bluebird Pharmaceuticals (ALD‐102, ALD‐103, and ALD‐104). ",

year = "2022",

month = may,

doi = "10.1002/mds.29018",

language = "English (US)",

volume = "37",

pages = "1109--1110",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Reply to “Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R-Related Leukoencephalopathy”

AU - Tipton, Philip W.

AU - Kenney-Jung, Daniel

AU - Rush, Beth K.

AU - Middlebrooks, Erik H.

AU - Nascene, David

AU - Singh, Balvindar

AU - Holtan, Shernan

AU - Ayala, Ernesto

AU - Broderick, Daniel F.

AU - Lund, Troy

AU - Wszolek, Zbigniew K.

N1 - Funding Information: E.H.M. receives research support from Mayo Clinic Focused Team Research program; Mayo Clinic Research Accelerator for Clinicians Engaged in Research program; Boston Scientific Corp; Varian Medical Systems, Inc.; and the National Institutes of Health (R33‐CA240181). He is also consultant for Boston Scientific Corp. Funding Information: Z.K.W. is partially supported by the NIH/NIA and NIH/NINDS (1U19AG063911, FAIN: U19AG063911), Mayo Clinic Center for Regenerative Medicine, and Mayo Clinic in Florida Focused Research Team Program and the gifts from the Donald G. and Jodi P. Heeringa Family and the Haworth Family Professorship in Neurodegenerative Diseases fund, the Albertson Parkinson's Research Foundation, and Ann B. Smith Research Fund. He serves as Principal investigator or co‐principal investigator for Biohaven Pharmaceuticals, Inc. (BHV4157‐206 and BHV3241‐301); Neuraly, Inc. (NLY01‐PD‐1); and Vigil Neuroscience, Inc. (VGL101‐01.001 and VGL101‐01.002). He serves as co‐PI for the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience, Inc. Funding Information: D.K.‐J. is partially supported by grants from the Rare Disease Foundation and CFC International and is Co‐I on Bluebird Pharmaceuticals (ALD‐102, ALD‐103, and ALD‐104).

PY - 2022/5

Y1 - 2022/5

KW - CSF1R-related leukoencephalopathy

KW - genetics; treatment

KW - stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=85130349092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130349092&partnerID=8YFLogxK

U2 - 10.1002/mds.29018

DO - 10.1002/mds.29018

M3 - Letter

C2 - 35587622

AN - SCOPUS:85130349092

SN - 0885-3185

VL - 37

SP - 1109

EP - 1110

JO - Movement Disorders

JF - Movement Disorders

IS - 5

ER -

Reply to “Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R-Related Leukoencephalopathy”

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this